Cabaletta Bio

Compare

1,300 Followers

CABA Stock Chart & Stats

$2.79

-$0.36(-13.38%)

At close: Jan 08 4:00 PM EST

$2.79

-$0.36(-13.38%)

Day’s Range― - ―

52-Week Range$0.99 - $5.46

Previous CloseN/A

Volume846.62K

Average Volume (3M)4.36M

Market Cap

$225.92M

Enterprise Value-$75.74M

Total Cash (Recent Filing)$194.68M

Total Debt (Recent Filing)$24.89M

Price to Earnings (P/E)―

Beta4.12

Next Earnings

Nov 12, 2025

EPS Estimate

-0.48

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.73

Shares Outstanding91,465,230

10 Day Avg. Volume3,443,196

30 Day Avg. Volume4,358,358

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.34

Enterprise Value/Revenue-46.24

Enterprise Value/Gross Profit135.73

Enterprise Value/Ebitda0.55

Forecast

1Y Price Target

$12.25

Price Target Upside339.07% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessPositive results from RESET trials show rese-cel driving remission and organ responses off immunosuppressants in SSc, SLE, and myositis.

FDA AlignmentCabaletta plans to align with FDA on a registrational cohort in systemic sclerosis, following positive early results in the RESET-SSc trial.

Preconditioning StrategyThe potential for administering rese-cel without preconditioning is seen as a significant competitive differentiator in treating autoimmune diseases.

Bears Say

Cabaletta Bio News

Cabaletta Bio presents data, development updates for Rese-cel

Cabaletta Bio (CABA) announced positive clinical data and development updates across the RESET-Myositis, RESET-SSc and RESET-SLE trials evaluating...

2d ago

CABA

Cabaletta Bio management to meet with Cantor Fitzgerald

Dinner Meeting with Management to be held in Chicago on October 27 hosted by Cantor Fitzgerald. Published first...

6d ago

CABA

Cabaletta Bio announces appointment of Gavel as CCO

Cabaletta Bio (CABA) announced the appointment of Steve Gavel as Chief Commercial Officer, CCO, effective immediately. In his...

15d ago

CABA

Cabaletta Bio jumps 30% to $3.13 after pemphigus vulgaris data

13:29 EDT Cabaletta Bio (CABA) jumps 30% to $3.13 after pemphigus vulgaris data Published first on TheFly –...

20d ago

CABA

Cabaletta Bio presents initial dose data from RESET-PV trial of rese-cel

Cabaletta Bio (CABA) presented initial dose data from the RESET-PV trial evaluating rese-cel at 1 x 106 cells/kg...

20d ago

CABA

Cabaletta Bio Updates on CD19-CAR T Therapy Progress

Cabaletta Bio ( ($CABA) ) just unveiled an update. On October 29, 2025, Cabaletta Bio released an updated...

2h ago

CABA

Cabaletta Bio’s Promising Clinical Advances and Strategic Plans Earn Buy Rating from Michael Ulz

Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Cabaletta Bio, retaining the price target of...

1d ago

CABA

Cabaletta Bio’s Innovative Myopathy Study: A Potential Game-Changer?

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. Study Overview: Cabaletta Bio, Inc. is...

2d ago

CABA

Cabaletta Bio’s Promising SLE Study: A Potential Game-Changer?

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-SLE is a Phase 1/2 open-label...

2d ago

CABA

Cabaletta Bio’s Promising Study on CABA-201 for Systemic Sclerosis: A Market Perspective

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. Study Overview: Cabaletta Bio, Inc. is...

2d ago

CABA

Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MG is a Phase 1/2 clinical...

2d ago

CABA

Cabaletta Bio’s Promising Clinical Trial Results Lead to Buy Rating

William Blair analyst Sami Corwin has maintained their bullish stance on CABA stock, giving a Buy rating today....

2d ago

CABA

Cabaletta Bio’s RESET-MS Study: A New Frontier in Multiple Sclerosis Treatment

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MS is a Phase 1/2 open-label...

2d ago

CABA

Cabaletta Bio’s Innovative Study on Pemphigus Vulgaris: A Potential Game-Changer

Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. Study Overview: Cabaletta Bio, Inc. is...

2d ago

CABA

CABA FAQ

What was Cabaletta Bio’s price range in the past 12 months?

Cabaletta Bio lowest stock price was $0.98 and its highest was $5.46 in the past 12 months.

What is Cabaletta Bio’s market cap?

Cabaletta Bio’s market cap is $225.92M.

When is Cabaletta Bio’s upcoming earnings report date?

Cabaletta Bio’s upcoming earnings report date is Nov 12, 2025 which is in 14 days.

How were Cabaletta Bio’s earnings last quarter?

Cabaletta Bio released its earnings results on Aug 07, 2025. The company reported -$0.73 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.08.

Is Cabaletta Bio overvalued?

According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cabaletta Bio pay dividends?

Cabaletta Bio does not currently pay dividends.

What is Cabaletta Bio’s EPS estimate?

Cabaletta Bio’s EPS estimate is -0.48.

How many shares outstanding does Cabaletta Bio have?

Cabaletta Bio has 91,465,230 shares outstanding.

What happened to Cabaletta Bio’s price movement after its last earnings report?

Cabaletta Bio reported an EPS of -$0.73 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Cabaletta Bio?

Currently, no hedge funds are holding shares in CABA

Cabaletta Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-76.34%

Trailing 12-Months

Asset Growth

3.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cabaletta Bio

Cabaletta Bio (CABA) is a biotechnology company focused on developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's core product pipeline involves utilizing its proprietary Chimeric AutoAntibody Receptor (CAAR) T cell technology to target and eliminate disease-causing B cells while preserving healthy B cells, aiming to provide a transformative impact on patients' lives.

Cabaletta Bio (CABA) Earnings & Revenues

Historic Earnings Reports

CABA Stock 12 Month Forecast

Average Price Target

$12.25

▲(339.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","23":"$23","5.75":"$5.75","11.5":"$11.5","17.25":"$17.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,5.75,11.5,17.25,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.31,3.8246153846153845,5.3392307692307694,6.853846153846154,8.368461538461538,9.883076923076924,11.397692307692308,12.912307692307694,14.426923076923078,15.941538461538462,17.456153846153846,18.970769230769232,20.485384615384614,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.31,3.0746153846153845,3.8392307692307694,4.603846153846154,5.368461538461538,6.133076923076922,6.897692307692308,7.662307692307692,8.426923076923076,9.191538461538462,9.956153846153846,10.72076923076923,11.485384615384616,{"y":12.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.31,2.286153846153846,2.2623076923076924,2.2384615384615385,2.2146153846153847,2.190769230769231,2.166923076923077,2.143076923076923,2.1192307692307693,2.0953846153846154,2.0715384615384616,2.0476923076923077,2.023846153846154,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.64,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >